Citations

Abstract Peritoneal Carcinomatosis (PC) is a metastatic cancer of the lining of the abdominal cavity, most often originating from the gastrointestinal or gynecological tracts. PC occurs in approximately 20% of colorectal cancer and 60% of ovarian cancer cases, with estimated 5-year survival rates as low as 6%. Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a locoregional drug delivery modality administered via a minimally invasive laparoscopic approach. PIPAC shows promise in the treatment of peritoneal metastasis in early trials on colorectal cancer (CRC) or appendiceal cancer (AC) in patients who cannot undergo cytoreductive surgery. The spatial organization of the tumor microenvironment (TME) and the complex cellular interactions within profoundly shape biology and treatment response. Spatial transcriptomics offers an opportunity to characterize TME heterogeneity in its native architecture, allowing the identification of biomarkers, interactions, and gene expression programs as well as resistance mechanisms and new potential targets. We performed image-based spatial transcriptomic profiling of 152 tissue samples, including 50 pre-treatment and 65 post-treatment metastatic tumors and 17 pre-treatment and 20 post-treatment tumor-adjacent normal tissue samples from 19 patients who participated in a Phase I trial on Oxaliplatin PIPAC. Through a comprehensive characterization of transcriptional profiles of a total of 1,249,711 cells, as well as cellular neighborhood and ligand-receptor interactions, we describe the heterogeneity of PC in its spatial context. We have further characterized treatment-driven changes in pre- and post-treatment tumors of a subset of 7 patients who underwent PIPAC with mitomycin IP. Through cell-based niche and proximity analyses, we identify distinct shifts in the composition and architecture of treated tumors. Most notably, treatment resulted in an 87% decrease in the number of malignant cells, as well as an expansion of the plasma-barrier niche and an increased number of immune infiltrates. Further analysis revealed distinct differences in the abundance of specific cancer-associated fibroblast and immune subsets, demonstrating changes in TME architecture. Overall, our results provide an invaluable characterization of PC in CRC and AC, garnering new insight into their architecture, cellular composition, and cell-cell interactions at baseline and in response to regional chemotherapy. Further analyses and follow-up studies can identify and validate new, actionable biomarkers to target these hard-to-treat tumors. Citation Format: Heini Maaret Natri, Arianna L. Williams-Katek, Muhammad Talha Waheed, Tiana Li, Marwan Fakih, Mingye Feng, Amit Merchea, Sue Chang, Richard L. Whelan, Danielle Deperalta, Thanh H. Dellinger, Nicholas Banovich, Mustafa Raoof. Spatial transcriptomic profiling of peritoneal metastases identifies multicellular programs in patient tumors undergoing pressurized intraperitoneal aerosol chemotherapy (PIPAC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3958.

Study Design Retrospective cohort study of a national database. Objectives This study investigates the association between preoperative antidepressant use and postoperative opioid utilization as well as overall outcomes following primary anterior cervical fusion (ACF) and posterior cervical fusion (PCF). Methods We conducted parallel retrospective cohort analyses utilizing TriNetX for patients aged ≥18 years old with ≥2-year follow-up undergoing primary ACF and PCF between December 31, 2006, and December 31, 2022. Cohorts were thoroughly matched resulting in 4575 ACF and 3497 PCF pairs. Medical outcomes, opioid abuse, healthcare utilization, mechanical and surgical outcomes were assessed through risk ratios (RR), risk differences, P -values, and Kaplan-Meier analysis. Results Antidepressant use was associated with increased new opioid prescriptions from 2 weeks to 2 years (ACF RR 1.090-1.130, P < 0.001; PCF RR 1.060-1.078, P < 0.001), higher hospital readmissions (RR 1.484, P < 0.001), prolonged inpatient stays (RR 1.329, P < 0.001), and ED visits from 6 weeks to 2 years (ACF RR 1.150-1.184, P < 0.001; PCF RR 1.092-1.144, P ≤ 0.034). Postoperative infections were elevated at 2 years (ACF RR 1.679-2.060, P ≤ 0.008; PCF RR 1.375-1.677, P ≤ 0.020). Opioid abuse was higher at 2 years (ACF RR 2.8000, P = 0.003; PCF RR 2.667, P = 0.001), and pulmonary embolism increased in ACF at 2 years (RR 1.633, P = 0.032). Reoperations were elevated at 1 and 2 years (RR 1.238-1.371, P ≤ 0.045), with reduced 2-year reoperation-free survival in ACF ( P = 0.001) and PCF ( P = 0.045). Conclusion Preoperative antidepressant use is associated with significantly increased risks of postoperative opioid utilization and both medical and surgical complications, including sepsis, infections, adjacent segment disease, and reoperations, up to 2 years after primary anterior or posterior cervical fusion.

AbstractBackgroundGastric cancer with synchronous peritoneal metastases is a debilitating disease with limited treatment options. This article describes an update of the 2018 Chicago Consensus guidelines addressing the management of gastric cancer with synchronous peritoneal metastases in line with the most recent evidence.MethodsA clinical management pathway was updated through two rounds of a Delphi consensus to assess agreement levels with pathway blocks. Supporting evidence underwent evaluation using a rapid literature review. Meta‐analyses were performed as appropriate.ResultsOverall, the level of evidence in this disease subset was low to moderate. Of 124 participants in the first round, 109 (88%) responded in the second round. Strong consensus (>90%) was achieved in six of eight blocks (75%) in rounds 1 and 2. A multidisciplinary preoperative assessment and diagnostic laparoscopy should be offered to all patients, whereas patients with a high burden of disease or progression should undergo nonsurgical management. Patients with stable/responsive disease and a low peritoneal carcinomatosis index should subsequently be offered treatment with regional therapeutic interventions and cytoreductive surgery. In patients who are cytology‐positive, systemic therapy can be used to convert them to cytology‐negative, with subsequent surgery offered according to the patient's goals of care. Meta‐analysis of observational and randomized control trials revealed a survival benefit with the addition of intraperitoneal chemotherapy to cytoreductive surgery (hazard ratio, 0.52).ConclusionsThe consensus‐driven clinical pathway for gastric cancer with synchronous peritoneal metastases offers vital clinical guidance for practitioners. There is a growing body of high‐quality evidence to support management strategies, and future clinical trials are eagerly awaited.